It’s been a year of putting patient centricity theory into practice, as companies and industry organisations alike have shared their advice and embraced emerging technologies.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh